# EBreast II





# Aseptic safety in breast patient care Part 1



#### Introduction

- This presentation is the first of two presentations focusing on enabling safe breast cancer patients' pathway from the Surgical Site Infection (SSI) prevention and control points of view.
- This first part introduces the main concepts in the microbiological safety, the overall, patient, and procedure related risks to SSIs in breast surgery.
- The second part discusses critical aseptic incidents, crucial for all the professionals working in the breast cancer patients' pathway.
- In part two, The Aseptic Practices in Breast Surgery –model serves as a structure for the practical implementation of the infection prevention and control measures in the breast patients' pathway.

#### Learning outcomes

After the two presentations, the learner is able to demonstrate

1) Critical knowledge of aseptic safety in breast surgery patient care.

2) Ability to implement patient and procedure specific infection prevention and control measures in breast surgery patient care.

3) Ability to guide the breast surgery patient and personnel to prevent, follow-up, and report surgical site infection related outcomes.



## Background

The breast cancer patients in this project, expected to have comprehensive and timely guidance and information related to their upcoming breast cancer pathway enabling them to prepare themselves "for what was to follow" (1).

The patients mentioned the outcomes of the breast surgery as positive experiences after their surgical procedures, and lack of follow-ups as negative experiences (1).

The health care professionals defined the competency of health care personnel performing surgery, trust on health care professionals, and clear information given to the patient of different aspects of surgery, the key factors related to a successful breast cancer pathway (2).

According to the EUSOMA, the breast patient's preoperative part of the care pathway consists of several hospital visits, discussions with multidisciplinary team members, and nurse counselling for diagnostic and surgical procedures (3, 4).

#### Introduction..

- Our retrospective patient chart survey revealed breaks in patients' pathways, particularly in infection prevention and control (IPC) documentation, follow-up and feedback (5).
- From the IPC points of view, the ability to argue patient information with evidence-based knowledge and the awareness of the cancer patient's whole perioperative process are key competencies in safe surgery performed by all professionals working on the pathway.(6,7).
- The critical use of local IPC data collected by hospital infection surveillance systems or professionals is important due to the biases in the local pathways, circumstances and resources. It is important to prevent the biases by structured follow-up measures.(5-9).

Definitions by The EU COUNCIL

- 'Adverse event' is an incident which results in harm to a patient.
- 'Harm' implies impairment of the structure or function of the body and/or any deleterious effect arising therefrom.
- 'Healthcare associated infection' (HAI) means diseases or pathologies related to the presence of an infectious agent or its products in association with exposure to healthcare facilities or healthcare procedures or treatments.
- 'Patient safety' means freedom, for a patient, from unnecessary harm or potential harm associated with healthcare.
- 'Process indicator' means an indicator referring to the compliance with agreed activities such as hand hygiene, infection surveillance, standard operating procedures (SOP).
- Structure indicator' means an indicator referring to any resource, such as staff, an infrastructure, or a committee.

#### Healthcare-associated infections (HAI) as a threat to patient safety

According to The European Disease Control and Prevention (ECDC):

"Healthcare-associated infections are infections acquired by patients during their stay in a hospital or another healthcare setting. Although some of these infections can be treated easily, others may more seriously affect a patient's health, increasing their stay in the hospital and hospital costs, and causing considerable distress to these patients."

• The most frequently reported types of healthcare-associated infections are:

Respiratory tract infections,

Surgical site infections (SSI),

Bloodstream infections and

Gastro-intestinal infections. (11)

# Definitions for SSI by ECDC

#### Superficial incisional infection:

- Infection occurs within 30 days after the operation involving only skin and subcutaneous tissue of the incision and at least one of the following:
- $\cdot$  purulent drainage with or without laboratory confirmation, from the superficial incision
- $\cdot$  organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision
- at least one of the following signs or symptoms of infection: pain or tenderness, localised swelling, redness, or heat and superficial incision is deliberately opened by surgeon, unless incision is culture-negative
   • diagnosis of superficial incisional SSI made by a surgeon or attending physician.

#### Deep incisional infection:

Infection occurs within 30 days after the operation if no implant is left in place or within 90 days if implant is in place and the infection appears to be related to the operation and infection involves deep soft tissue (e.g. fascia, muscle) of the incision and at least one of the following:

 $\cdot$  purulent drainage from the deep incision but not from the organ/space component of the surgical site

 a deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following signs or symptoms: fever (> 38°C), localised pain or tenderness, unless incision is culture-negative
 an abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by histopathologic or radiologic examination

· diagnosis of deep incisional SSI made by a surgeon or attending physician.

#### Organ/space infection:

Infection occurs within 30 days after the operation if no implant is left in place or within 90 days if implant is in place and the infection appears to be related to the operation and infection involves any part of the anatomy (e.g. organs and spaces) other than the incision that was opened or manipulated during an operation and at least one of the following:

- $\cdot$  purulent drainage from a drain that is placed through a stab wound into the organ/space
- $\cdot$  organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space
- $\cdot$  an abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination
- · diagnosis of organ/space SSI made by a surgeon or attending physician.

#### Risk Factors for surgical site infections

According to ECDC, in European countries the patient's SSI risk index is the index used in the US National Healthcare Safety Network (NHSN) and assigns the surgical patients into categories based on the presence of three major risk factors 1) Wound contamination class, 2) ASA classification by American Society of Anaesthesiologists, and 3) Duration of operation. (11 -13)

Calculation	Score =0, if	Score=1, if:
Wound contamination class	W1, W2	W3, W4
ASA classification	A1, A2	A3, A4, A5
Duration of operation under 75th percentile cut-off value in hours	≤ 75th percentile cut-off value in hours	> 75th percentile cut-off value in hours
Basic SSI risk index	= Sum of scores	Max 3= Sum of scores

(11)

Wound contamination class	Description
W1	<ul> <li>A clean wound is an uninfected operative wound in which no inflammation is encountered and the respiratory, alimentary, genital or uninfected urinary tracts are not entered.</li> <li>In addition, clean wounds are primarily closed and, if necessary, drained with closed drainage. Operative incisional wounds that follow non-penetrating trauma should be included in this category.</li> </ul>
W2	<b>Clean-contaminated wounds</b> are operative wounds in which the respiratory, alimentary, genital or uninfected urinary tracts are entered under controlled condition and without unusual contamination. Specifically operations involving the biliary tract, appendix, vagina and oropharynx are included in this category provided no evidence of infection or major break in technique is encountered.
W3	<b>Contaminated wounds</b> include open, fresh, accidental wounds. In addition operations with major breaks in sterile technique or gross spillage from the gastrointestinal tract, and incisions in which acute, nonpurulent inflammation is encountered are included in this category.
W4	<b>Dirty or infected wounds</b> include old traumatic wounds with retained devitalised tissue and those that involve existing clinical infection or perforated viscera. This definition suggests that the organisms causing postoperative infection were present in the operative field before the operation.

(11-13)

# Generic risk factors for SSI

In addition to the classical SSI risks also more detailed procedure and patient specific risks have been reported in several studies.

Patient related risk factors for surgical site infections		
Age		
Male gender		
Nutritional status		
Diabetes		
Smoking		
Obesity		
Coexistent infections at a remote body site		
Colonization with microorganisms		
Altered immune response		
Length of preoperative stay in hospital		
Medication		
Hypothermia		
Reduced blood flow following hemorrhage		
Reduced subcutaneous perfusion and oxygenation		
Operation related risk factors for surgical site infections		
Preoperative skin preparations		
Preoperative shaving		
Skin antisepsis		
Duration of surgical scrub		
Duration of operation		
Antimicrobial prophylaxis		
Operating room ventilation		
Inadequate sterilization of instruments		
Foreign material in the surgical site		
Surgical drains		
Surgical technique		
Poor hemostasis		
Failure to obliterate dead space		
Tissue trauma		
Emergency of the operation		

(6 with permission of the copy right holder)

\*Modified from Haley et al. 1985a; Haley 1991; Chaudry & Ayala 1992; Hyrylä 1993; Hopf et al. 1997; Kamph et al. 1997; Mangram et al. 1999; Safdar et al. 2003; Moro et al. 2005; Palma et al. 2006; Rioux et al. 2006 & 2007; Gordon et al. 2009; Couris et al. 2007; Alexander et al. 2011; Beltramini et al. 2011; Berríos-Torres et al. 2017.

# SSI in breast surgery

- "Breast operations" cover a variety of surgical procedures from local excisions to mastectomies without or with immediate or delayed reconstructions each having patient and procedure specific consequences to breast operated patients, particularly SSIs (14).
- The SSI risk index makes the risks related outcomes clearly visible. After mastectomies, the SSI rates reported as 2.07% in risk index category 0 & 1, and 3.97% in risk index category 2 & 3 respective (15).
- ➢ In large scale breast surgery outcome studies the expected SSI rates in these "clean surgery" operations reported between 2% and 4%. (9,16,17).
- In the US, the SSI rates in breast surgery are traditionally reported varying from 1 % to 2%. The rates are lower than in Europe or elsewhere outside the US varying for example from 0% (8) near to 20% (18). This may be due to weaknesses in postoperative follow-up, quality problems in perioperative care or variation in the patient and procedure related risks. (6).

#### Surgical site infection rates and risks in breast operations.

Mastectomy         (N=9,486) (N=665)         1.7 5.0         Risk index 0,1 Pitsk index 2,3         NNIS system October 1986 - April 1986           Mastectomy         (N=11,176)         2.1         Risk index 0,1 Pitsk index 2,3         NNIS system October 1986           Mastectomy         (N=13,623)         1.9         Risk index 0,1 Pitsk index 2,3         NNIS system October 1986           Mastectomy         (N=13,623)         1.9         Risk index 0         NNIS system January 1992           Mastectomy         (N=13,623)         1.9         Risk index 1         June 2002           Mastectomy         (N=16,267)         1.8         Risk index 1         June 2002           Mastectomy         (N=16,277)         1.8         Risk index 1         June 2004           Mastectomy         (N=11,20)         2.2         Risk index 1         June 2004           Mastectomy         (N=1,123)         3.0         NNIS risk index 2-3         NNIS 2004 (US           Mastectomy         (N=1,133)         NNIS risk index 2-3         NNIS 2004 (US         NNIS 2004 (US           Mastectomy         (N=1,132)         8.9         NNIS risk index 2-3         NNIS 2004 (US         NNIS 2004 (US           Mastectomy         (n=1,122)         8.9         NNIS risk 0, pPOS         Relity et al. 2006 (	Type and number (N) of operations	SSI rate	Risks, operation and follow-up characteristics	Reference
United point 2 h         NNIS 1999 (US)           Mastectomy         (N=11,176) (N=403)         2.1         Risk index 0,1         NNIS system January 1990           Mastectomy         (N=13,623) (N=6509)         1.9         Risk index 2.3         NNIS system January 1992           Mastectomy         (N=13,623)         1.9         Risk index 2.3         NNIS 2004 January 1992           (N=6509)         2.3         Risk index 1         June 2002         NNIS 2004 January 1992 - June 2002           Mastectomy         (N=16,287)         1.8         Risk index 2.3         NNIS 2004 January 1992 - June 2004           (N=10,700)         2.2         Risk index 1         June 2004         NNIS 2004 (US)           Mastectomy         (N=1,122)         3.4         Duration out point 3 h         NNIS 2004 (US)           Mastectomy         (N=1,33)         1.1.7         4-year surveillance         Brandt et al. 2005 (Italy)           Mastectomy         (N=1,33)         1.1.7         4-year surveillance         Brandt et al. 2005 (UK)           PDS completed         (n=11,22)         8.9         NNIS risk 10, PDS         Relily et al. 2006 (UK)           No PDS completed         (n=215)         0.9         NNIS risk 2.1, no PDS         Relily et al. 2006 (UK)           Mastectomy / mammary	Mastectomy (N=9,486) (N=665)	1.7	Risk Index 0,1 Risk Index 2,3	NNIS system October 1986 – April 1998
Mastectomy         (N=11,17) (N=403)         2.1 4.0         Risk Index 0,1 Fisk Index 0,1 Duration cut point 3 h         NNIS system January 1990 NNIS 1999 (US)           Mastectomy         (N=13,623) (N=6509)         1.9 (N=6509)         Risk Index 1 Zisk Index 2,3 Duration cut point 3 h         NNIS system January 1992 NNIS 1999 (US)           Mastectomy         (N=16,287) (N=10,700)         1.8 Zisk Index 2,3 Duration cut point 3 h         NNIS 2002 (US)           Mastectomy         (N=16,287) (N=10,700)         1.8 Zisk Index 2,3 Duration cut point 3 h         NNIS 2002 January 1992 - June 2004 January 1992 - June 2004 January 1992 - June 2004 (US)           Mastectomy         (N=1,12)         3.4 Risk Index 0 (N=1,12)         NNIS risk Index 0 Duration cut point 3 h         NNIS 2002 (US)           Mastectomy         (N=7449)         1 - 1.7         4-year survellance         Brandt et al. 2005 (Italy)           Mastectomy (m=1,388)         9 No PDS completed (n=114)         0 NNIS risk 0, PDS         Relily et al. 2006 (UK)           Mastectomy / mammary tumorectomy (m=2,438)         2.7         Rioux et al. 2007 (France)         Risk: right BNI, DMI Singht, central venous catheter         Cisen et al. 2008 (US)           Mastectomy + reconstruction Mastectomy only Ereast cancer operations (N=2,338)         18.9         Risks: right BNI, DMI Singht, central venous catheter         Angarta et al. 2011 (Columbia)           Breast cancer operations (N=2,97) <t< td=""><td> ,</td><td></td><td>Duration cut point 2 h</td><td>NNIS 1999 (US)</td></t<>	,		Duration cut point 2 h	NNIS 1999 (US)
(N=403)         4.0         Risk Index 2.3        May 1999           Mastectomy         (N=3,62)         1.9         Risk Index 1         NNIS 1999 (US)           Mastectomy         (N=3,62)         2.3         Risk Index 1         -June 2002           Mastectomy         (N=636)         3.4         Risk Index 2.3         NNIS 2004 January 1992 - June 2004           Mastectomy         (N=16,287)         1.8         Risk Index 2.3         NNIS 2004 January 1992 - June 2004           (N=10,700)         2.2         Risk Index 2.3         NNIS 2004 January 1992 - June 2004         NNIS 2004 (US)           Mastectomy         (N=1,112)         3.4         Risk Index 2-3         Duration out point 3 h         NNIS 2004 (US)           Mastectomy         (N=744)         1-1.7         4-year surveillance         Brandt et al. 2005 (Italy)           PDS completed         (n=112)         8.9         NNIS risk Index 2-3         More et al. 2006 (UK)           NO PDS completed         (n=721)         8.9         NNIS risk Index 2-3         Relily et al. 2006 (UK)           Mastectomy / mammary         (n=27)         7.4         NNIS risk Index 2-3         Relily et al. 2007 (France)           Breast persotions (N=49)         (n=2,438)         2.7         Risk: Chemo radiation, heastectomy et al. 2007 (Fra	Mastectomy (N=11,178)	2.1	Risk Index 0,1	NNIS system January 1990
Duration cut point 3 h         NNIST system January 1992 (JS)           Mastectomy         (N=13,623) (N=635)         1.9 (N=635)         Risk Index 2,3 Risk Index 2,3 (N=035)         NNIST system January 1992 (JS)           Mastectomy         (N=16,267) (N=10,700)         1.8 (N=10,700)         Risk Index 1 Risk Index 1 (N=11,112)         NNIST system January 1992 (JS)           Mastectomy         (N=16,267) (N=10,1112)         1.8 (N=10,100)         Risk Index 1 Risk Index 1 Duration cut point 3 h         NNIS 2004 January 1992 (JS)           Mastectomy         (N=1,112)         3.4 (N=1,112)         Risk Index 2.3 Duration cut point 3 h         NNIS 2004 January 1992 (JS)           Mastectomy         (N=311)         1.9 (N=173)         NNIS risk Index 2-3 Duration cut point 3 h         NNIS 2004 (US)           Mastectomy         (N=744)         1.1.7         4-year surveiliance         Brandt et al. 2006 (Germany)           Breast operations         (N=743)         8.9 (n=752)         NNIS risk 0, no PDS (n=104)         Relily et al. 2006 (UK)           NO PDS completed (n=174)         0 (n=174)         NNIS risk 2.1, no PDS         Rioux et al. 2007 (France)           Breast operations (N=499) Mastectomy + maptant (n=27)         7.7         Risks: NdB MI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N=2,336)         1.9         Risks: high BMI,	(N-403)	4.0	Risk Index 2,3	– May 1999
Mastectomy         (N=13,623) (N=630)         1.9 (N=635)         Risk Index 1 Risk Index 2,3 Duration out point 3 h         NNIS System January 1992 - June 2002 NNIS 2002 (US)           Mastectomy         (N=16,267) (N=10,700)         1.8 (N=10,700)         Risk Index 2,3 Duration out point 3 h         NNIS 2004 January 1992 - June 2004           Mastectomy         (N=1,112)         3.4 (N=1,112)         Risk Index 2-3 Duration out point 3 h         NNIS 2004 (US)           Mastectomy         (N=1,122)         8.9 (N=1,122)         NNIS fisk Index 2-3 Duration out point 3 h         Noro et al. 2005 (Italy)           Mastectomy         (N=7449)         1-1.7 4-year surveiliance         Brandt et al. 2006 (Germany)           Breast operations         (N=1,122)         8.9 (N=1742)         NNIS fisk 0, PDS           NO PDS completed         (n=2,16)         0 (n=174)         NNIS fisk 0, PDS           Mastectomy / mammary tumorectomy         (n=2,438)         2.7         Risks: OM, BMI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N=2,336)         18.9         Risks: Chemo radiation, hematioma, BMI > 30, Uuration out point > 3h         Vilar-Compte et al. 2009 (Mexicol           Breast cancer operations (N=199)         19.1         Risks: Nigh BMI, DM, smoking, skin disorder, tumore at ligh stage, necoadjuvant therapy encoadiuvant therapy necoadiuvant therapy (N=36,779)         Adetayo et al.			Duration cut point 3 h	NNIS 1999 (US)
(N=6,809)         2.3         Risk index 1         - June 2002           Mastectomy         (N=6,85)         3.4         Risk index 2,3         NNIS 2002 (US)           Mastectomy         (N=16,287)         1.8         Risk index 2,3         NNIS 2004 (US)           Mastectomy         (N=11,112)         3.4         Risk index 2,3         NNIS 2004 (US)           Mastectomy         (N=311)         1.9         NNIS risk index 2-3         NNIS 2004 (US)           Mastectomy         (N=7449)         1-1.7         4-year surveillance         Brandt et al. 2006 (Germany)           Breast operations         (N=1,336)         POS completed         n=1.12         8.9           No PDS completed         (n=216)         0.9         NNIS risk 0, no PDS         Relity et al. 2006 (UK)           Mastectomy / mammary         (n=27)         3.7         NNIS risk 0, no PDS         Relity et al. 2007 (France)           Breast operations (N=449)         1.1         12.4         Risks: index MI > 30, implant, central venous catheter         Olsen et al. 2008 (US)           Mastectomy + Implant         12.4         Risks: inde MI > 30, implant, central venous catheter         Olsen et al. 2009 (Wextor)           Breast cancer operations (N=297)         7.7         Risks: high BMI, 50, Mextor)         Olsen et al. 2011 (Columbla) <td>Mastectomy (N=13,623)</td> <td>1.9</td> <td>Risk Index 0</td> <td>NNIS system January 1992</td>	Mastectomy (N=13,623)	1.9	Risk Index 0	NNIS system January 1992
(N=835)         3.4         Prisk index 2.3 Duration out point 3 h         NNIS 2002 (US)           Mastectomy         (N=16,287) (N=10,700)         1.8         Risk index 0         NNIS 52004 January 1992 – June 2004           Mastectomy         (N=1,112)         3.4         Risk index 0         NNIS 5800 January 1992 – June 2004           Mastectomy         (N=1,112)         3.4         Risk index 2-3 Duration out point 3 h         NNIS 7804 (US           Mastectomy         (N=7449)         1-1.7         4-year surveiliance         Brandt et al. 2006 (Germany)           Breast operations         (N=1,333)         NNIS fisk index 0-1 NNIS fisk 0, PDS         Brandt et al. 2006 (UK)           No PDS completed         (n=172)         8.9 (n=752)         NNIS fisk 0, PDS         Relify et al. 2006 (UK)           Mastectomy / mammary tumorectomy         (n=27)         3.7         NNIS fisk 0, no PDS         NIS fisk 21, PDS           Mastectomy + Implant         12.4 (n=27)         Risks: EMB 1> 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N=2,338)         18.9         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy         Angarta et al. 2012 (US)           Breast cancer operations (N=297)         7.7         Risks: BMI >30, Duration cut point > 3h         Adetayo et al. 2012 (US)	(N=8,509)	2.3	Risk Index 1	- June 2002
Mastectomy         (N=16,267) (N=10,700)         1.8 2.2 (N=1,112)         Risk index 0 3.4         NNIS 2004 January 1992 – June 2004           Mastectomy         (N=311)         1.9 3.0         Risk index 2-3 Duration cut point 3 h         NNIS 2004 (US           Mastectomy         (N=311)         1.9 3.0         NNIS fisk index 2-3 Duration cut point 3 h         More et al. 2005 (Italy)           Mastectomy         (N=7449)         1-1.7         4-year surveiliance         Brandt et al. 2006 (Germany)           Breast operations         (N=1,33) (n=72)         8.9 (n=752)         NNIS fisk 0, PDS (n=752)         Relily et al. 2006 (UK)           NO PDS completed (n=714)         (n=2,43)         2.7         Risk index 2-3 NNIS fisk 2, PDS NNIS fisk 2, PDS NNIS fisk 2, no PDS         Relive et al. 2007 (France)           Breast operations (N=949) Mastectomy + mammary Lumorectomy (n=2,438)         12.4 (Risks: CM, BMI > 30, Implant, central venous catheter         Oisen et al. 2008 (US)           Breast cancer operations (N=2,338)         18.9         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjurant therapy         Angarita et al. 2011 (Columbia)           Breast cancer operations (N=297)         7.7         Risks: high BMI, DM, smoking, skin disorder, tumor at high stage, neoadjurant therapy         Angarita et al. 2012 (US)           Breast operations (N=2698)         5.6         High BMI, Smoking, DM, previous reoperation	(N=835)	3.4	Risk index 2,3 Duration out point 3 h	NNIS 2002 (US)
Instruction         (N=10,700) (N=1,112)         2.2 3.4         Risk index 1 Risk index 2-3 Duration out point 3 h NNIS fisk index 2-3         June 2004 NNIS 2004 (US           Mastectomy         (N=311)         1.9         NNIS fisk index 0-1 NNIS fisk index 2-3         More et al. 2005 (Italy)           Mastectomy         (N=7449)         1.1.7         4-year surveillance         Brandt et al. 2006 (Germany)           Breast operations         (N=1,122) (n=752)         8.9 (n=752)         NNIS fisk 0, PDS         Relily et al. 2006 (UK)           No PDS completed (n=104)         (n=1,122) (n=752)         8.9 (n=724)         NNIS fisk 0, PDS         Relily et al. 2006 (UK)           Mastectomy / mammary tumorectomy         (n=2,13)         2.7         Risks: DN, BMI > 30, Mastectomy + reconstruction         Risks: DN, BMI > 30, Duration cut point > 3h         Olsen et al. 2008 (US)           Breast cancer operations (N=249)         18.9         Risks: chemo radiation, hematoma, BMI > 30 Duration cut point > 3h         Vilar-Compte et al. 2009 (Mexico)           Breast cancer operations (N=297)         7.7         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuwart therapy         Angarta et al. 2012 (US)           Breast concerving operations (N=25,988)         5.6 High BMI, Smoking, DM, previous re-operation         Adetayo et al. 2012 (US)           Breast conserving operations (N=38,739)         2.3         Previous re	Mastectomy (N=16.287)	1.8	Risk index 0	NNIS 2004 January 1992 -
(N=1,112)         3.4         Risk Index 2-3 Duration cut point 3 h         NNIS 2004 (US           Mastectomy         (N=7449)         1-1.7         4-year surveillance         Brandt et al. 2005 (Italy)           Mastectomy         (N=7449)         1-1.7         4-year surveillance         Brandt et al. 2006 (Germany)           Breast operations         (N=1,122)         8.9         NNIS risk 0, PDS         Relify et al. 2006 (UK)           No PDS completed         (n=1122)         8.9         NNIS risk 0, PDS         Relify et al. 2006 (UK)           (n=104)         0         NNIS risk 0, PDS         Relify et al. 2007 (France)         Relify et al. 2007 (France)           Mastectomy / mammary tumorectomy         (n=-2,438)         2.7         Risks: DM, BMI > 30, Implant, 0, entral venous catheter         Olsen et al. 2008 (US)           Mastectomy + reconstruction         6.2         Implant, 0, entral venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N=2,338)         18.9         Risks: high BMI, DM, smoking, BM, 30         Ular-Compte et al. 2009 (Mexico)           Breast cancer operations (N=2,37)         7.7         Risks: high BMI, DM, smoking, DM, previous re-operation         Adetayo et al. 2012 (US)           Breast reconstructions (N=26,988)         5.6         High BMI, Smoking, DM, previous re-operation         Adetayo et al. 2012 (US)	(N=10,700)	2.2	Risk Index 1	June 2004
Duration cut point 3 h           Mastectomy         (N=311)         1.9         NNIS risk index 0-1         More et al. 2005 (italy)           Mastectomy         (N=7449)         1 -1.7         4-year surveillance         Brandt et al. 2006 (Germany)           Breast operations         (N=7133)         0.9         NNIS risk index 2-3         Brandt et al. 2006 (UK)           Reilly et al. 2006 (UK)         0.9         NNIS risk 0, PDS         Reilly et al. 2006 (UK)           No PDS completed         (n=714)         0.9         NNIS risk 0, no PDS         Reilly et al. 2007 (France)           Mastectomy / mammary tumorectomy         (n=2.438)         2.7         Risks: DM, BMI > 30, Implant, central venous catheter         Oisen et al. 2007 (France)           Breast operations (N=949)         1.1         Risks: CDM, BMI > 30, Implant, central venous catheter         Vilar-Compte et al. 2008 (US)           Breast cancer operations (N=2,338)         18.9         Risks: chemo radiation, hematoma, BMI > 30 Duration cut point > 3h         Vilar-Compte et al. 2009 (Mexico)           Breast cancer operations (N=297)         7.7         Risks: high BMI, DM, stroking, skin disorder, umpectomy (n=16,517)         Adetayo et al. 2012 (US)           Breast reconstructions (N=26,988)         5.6         High BMI, Smoking, DM, previous reoperation         Adetayo et al. 2013 (US)           Breast-conserving operat	(N-1,112)	3.4	Risk Index 2-3	NNIS 2004 (US
Mastectomy         (N=311)         1.9         NNIS risk index 0-1 NNIS risk index 2-3         More et al. 2005 (Italy)           Mastectomy         (N=7449)         1-1.7         4-year surveillance         Brandt et al. 2005 (Germany)           Breast operations         (N=1,338)         8.9         Relily et al. 2006 (UK)           No PDS completed         (n=716)         0.9         Relily et al. 2006 (UK)           (n=104)         0         NNIS risk 0, PDS         Relily et al. 2006 (UK)           (n=174)         18.4         NNIS risk 0, PDS         Relily et al. 2007 (France)           Breast operations         (N=27)         3.7         NNIS risk 0, no PDS         Rioux et al. 2007 (France)           Breast operations (N=349)         12.4         Risks: DM, BMI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Mastectomy + mighant         12.4         Risks: chemo radiation, hematoma, BMI > 30         Vilar-Compte et al. 2009 (Mexico)           Breast cancer operations (N=2,338)         18.9         Risks: high BMI, DM, smoking, Skin disorder, uneoadjuvant therapy         Adetayo et al. 2012 (US)           Breast cancer operations (N=26,988)         5.6         High BMI, Smoking, DM, previous re-operation         Adetayo et al. 2012 (US)           Breast reconstructions (N=26,988)         5.6         High BMI, Smoking, DM, previous re			Duration cut point 3 h	-
Mastectomy         (N-7449)         1-1.7         4-year surveillance         Brandt et al. 2005 (Germany)           Breast operations         (N-1,122)         8.9         NNIS risk 0, PDS         Relily et al. 2006 (UK)           No PDS completed         (n-1,122)         0.9         NNIS risk 0, PDS         Relily et al. 2006 (UK)           (n-752)         7.4         NNIS risk 0, no PDS         NNIS risk 1, no PDS         Relive t al. 2007 (France)           Mastectomy / mammary         (n-27)         3.7         NNIS risk 2, no PDS         Rioux et al. 2007 (France)           Breast operations (N-949)         12.4         Risks: DM, BMI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Mastectomy + reconstruction         6.2         Implant, central venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N-2,338)         18.9         Risks: righ BMI, DM, skin disorder, tumour at high stage, neoadjuvant therapy         Angartta et al. 2011 (Columbia)           Breast cancer operations (N-2597)         7.7         Risks: Nigh BMI, DM         Angartta et al. 2012 (US)           Breast operations (N-26,988)         5.6         High BMI, Smoking, DM         Adetayo et al. 2012 (US)           Mastectomy (n=16,517)         1.6         Risks: BMI >25; ASA <u>&gt;3;</u> DM; operation time> 75 <sup>m</sup> pericontime> 75 <sup>m</sup> percentile (> 2 h), smoking         Davis	Mastectomy (N=311)	1.9	NNIS risk Index 0-1	Moro et al. 2005 (Italy)
Mastectomy         (N-7449)         1 -1.7         4-year surveillance         Brandt et al. 2006 (Germany)           Breast operations         (N-1,338)         11.7         4-year surveillance         Brandt et al. 2006 (Germany)           PDS completed         (n-11,32)         8.9         Relily et al. 2006 (UK)           No PDS completed         (n-752)         7.4         NNIS risk 0, no PDS         Relily et al. 2006 (UK)           (n-174)         18.4         NNIS risk 21, PDS         Rioux et al. 2007 (France)         Breast operations (N-949)           Mastectomy + maptant         12.4         Risks: DM, BMI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Mastectomy + implant         12.4         Risks: chemo radiation, hematoma, BMI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N-2,338)         18.9         Risks: chemo radiation, hematoma, BMI > 30, Implant, skin disorder, tumour at high stage, necadjuvant therapy         Angarita et al. 2011 (Columbia)           Breast cancer operations (N-297)         7.7         Risks: high BMI, DM, smoking, Skin disorder, tumour at high stage, necadjuvant therapy         Adetayo et al. 2012 (US)           Breast operations (N-26,988)         5.6         High BMI, Smoking, DM, previous re-operation         Adetayo et al. 2012 (US)           Breast operations (N-26,988)         2.3 <td></td> <td>3.0</td> <td>NNIS risk index 2-3</td> <td></td>		3.0	NNIS risk index 2-3	
Breast operations         (N=1,338) (n=752)         Relily et al. 2006 (UK)           No PDS completed         (n=716)         0.9 (n=752)         NNIS risk 0, PDS (n=174)         Relily et al. 2006 (UK)           Mastectomy / mammary tumorectomy (m=1,438)         (n=27)         3.7         NNIS risk 21, PDS NNIS risk 21, PDS NNIS risk 21, no PDS         Rioux et al. 2007 (France)           Breast operations (N=949) Mastectomy + reconstruction Mastectomy + reconstruction Mastectomy noise         12.4         Risks: DM, BMI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N=2,338)         18.9         Risks: chemo radiation, hematoma, BMI > 30, Duration cut point > 3h         Vilar-Compte et al. 2009 (Mexico)           Breast cancer operations (N=297)         7.7         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy         Angarita et al. 2011 (Columbia)           Breast concer operations (N=297)         7.7         Risks: high BMI, SM previous re-operation         Adetayo et al. 2012 (US)           Breast operations (N=26,988)         5.6         High BMI, Smoking, DM, previous re-operation         Davis et al. 2013 (US)           Breast-conserving operations (N=38,739)         2.3         Risks: BMI >25; ASA <u>&gt;3;</u> DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations (N=72,058)         3.6 Mastectomy (n=3,4477)         90 day	Mastectomy (N=7449)	1 -1.7	4-year surveillance	Brandt et al. 2006 (Germany)
PDS completed         (n=1,122) (n=752)         8.9 (n=752)         Relity et al. 2006 (UK)           No PDS completed         (n=752) (n=104)         0 0         NNIS risk 0, no PDS NNIS risk 0, no PDS         Relity et al. 2006 (UK)           Mastectomy / mammary tumorectormy         (n=2,438)         2.7         Rioux et al. 2007 (France)           Breast operations (N=949) Mastectomy + implant         12.4 Mastectomy + implant         Risks: DM, BMI > 30, Duration cut point > 3h         Olsen et al. 2008 (US)           Breast reduction         6.2 Mastectomy only         Risks: chemo radiation, hematom, BMI > 30, Duration cut point > 3h         Vilar-Compte et al. 2009 (US)           Breast cancer operations (N=2,338)         18.9         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy         Angarita et al. 2011 (Columbia)           Breast reconstructions (N=297)         7.7         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy         Adetayo et al. 2012 (US)           Breast operations (N=26,88) Mastectomy (n=16,517)         1.6         High BMI, Smoking, DM, previous re-operation         Adetayo et al. 2013 (US)           Breast-conserving operations (N=38,739)         2.3         Diff operation time> 75 <sup>h</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations (N=2,055)         2.4         90 day SSI rate         Olsen et al. 2015 (US)	Breast operations (N=1,338)			
No PUS completed         (II=216) (II=72)         0.9 (II=104)         NNIS risk 0, PDS NNIS risk 0, no PDS NNIS risk 21, PDS NNIS risk 21, PDS           Mastectomy / mammary tumorectomy (II=2,438)         18.4         NNIS risk 21, PDS NNIS risk 21, no PDS         Rioux et al. 2007 (France)           Breast operations (N=949) Mastectomy + implant         12.4         Risks: DM, BMI > 30, Implant, central venous catheter         Oisen et al. 2008 (US)           Breast concer operations (N=2,338)         18.9         Risks: chemo radiation, hematoma, BMI >30, Uuration cut point > 3h         Vilar-Compte et al. 2009 (Mexico)           Breast cancer operations (N=199)         19.1         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy         Angarita et al. 2011 (Columbia)           Breast reconstructions (N=297)         7.7         Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy         Adetayo et al. 2012 (US)           Breast operations (N=297)         7.7         Risks: BMI >25, SAS ≥3; DM; operation time> 75 <sup>m</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations (N=38,739)         2.3         Risks: BMI >25, SAS ≥3; DM; operation time> 75 <sup>m</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations (N=72,058)         3.6         90 day SSI rate         Oisen et al. 2015 (US)           Breast-conserving (I=0,477)         1.8         90 da	PDS completed (n=1,122)	8.9		Relly et al. 2006 (UK)
(n + 104) (n = 174) (n = 174)         1.0 (n = 27)         NNIS risk 0, no PDS NNIS risk ≥1, PDS NNIS risk ≥1, PDS           Mastectomy / mammary tumorectomy         (n = 2, 438)         2.7         Rioux et al. 2007 (France)           Breast operations (N=949) Mastectomy + reconstruction Mastectomy + reconstruction Mastectomy + reconstruction Mastectomy + reconstruction         12.4 6.2 4.4         Risks: DM, BMI > 30, Implant, central venous catheter         Olsen et al. 2008 (US)           Breast cancer operations (N=2,338)         18.9         Risks: chemo radiation, hematoma, BMI > 30 Duration cut point > 3h         Vilar-Compte et al. 2009 (Mexico)           Breast cancer operations (N=2,338)         18.9         Risks: high BMI, DM, smoking, skin disorder, neoadjuvant therapy         Angarita et al. 2011 (Columbia)           Breast cancer operations (N=297)         7.7         Risks: high BMI, DM, smoking, skin disorder, neoadjuvant therapy         Angarita et al. 2012 (US)           Breast constructions (N=297)         7.7         Risks: BMI > 25; ASA ≥ 3; Dift operations (N=06,988)         Adetayo et al. 2012 (US)           Mastectomy no reconstruction (N=38,739)         2.3         DM; operation time > 75 <sup>m</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations Primary operation (n=23,001)         1.8         90 day SSI rate         Oisen et al. 2015 (US)           Breast-conserving (n=-3,447)         2.3         90 day SSI rate         Oisen et al.	No PUS completed (n=216) (n=752)	7.4	NNIS risk 0, PDS	
(n=174) (n=27)       18.4 3.7       NNIS risk ≥1, PDS NNIS risk ≥1, no PDS         Mastectomy / mammary tumorectomy       (n=2,438)       2.7       Rioux et al. 2007 (France)         Breast operations (N=949) Mastectomy + Implant       12.4 Mastectomy + reconstruction Mastectomy only       Risks: DM, BMI > 30, implant, central venous catheter       Olsen et al. 2008 (US)         Breast reduction       1.1       Risks: chemo radiation, hematoma, BMI > 30, Duration cut point > 3h       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N=2,338)       18.9       Risks: chemo radiation, hematom, BMI > 30, Duration cut point > 3h       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N=2,338)       19.1       Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Angarita et al. 2011 (Columbia)         Breast reconstructions (N=297)       7.7       Risks: high BMI, DM, Mastectomy (n=10,471)       Adetayo et al. 2012 (US)         Breast operations (N=26,988) Mastectomy no reconstruction (N=38,739)       2.3       Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking       Davis et al. 2013 (US)         Breast-conserving operations Primary operations (N=72,058)       1.8 Re-operation (n=5,26)       90 day SSI rate       Olsen et al. 2015 (US)         Breast-conserving (n=4,05)       4.8 Mastectomy + flap       (n=4,05)       4.8 Reaction       90 day SSI rate       Olsen et al. 2015 (US	(n=104)	0	NNIS risk 0, no PDS	
(n=27)         3.7         NNIS risk ≤1, no PDS           Mastectomy / mammary tumorectomy         (n=2,438)         2.7         Rioux et al. 2007 (France)           Breast operations (N=949) Mastectomy + Implant Mastectomy versions (number of the state of the s	(n=174)	18.4	NNIS risk >1, PDS	
Mastectomy (n=2,438)       2.7       Rioux et al. 2007 (France)         Breast operations (N=949)       12.4       Risks: DM, BMI > 30, Implant, central venous catheter       Olsen et al. 2008 (US)         Mastectomy + reconstruction       6.2       Implant, central venous catheter       Olsen et al. 2008 (US)         Breast reduction       1.1       Risks: chemo radiation, hematoma, BMI > 30, Duration cut point > 3h       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N=2,338)       18.9       Risks: chemo radiation, hematoma, BMI > 30, Duration cut point > 3h       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N=199)       19.1       Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Angarita et al. 2011 (Columbia)         Breast reconstructions (N=297)       7.7       Risks: high BMI, Smoking, DM, previous re-operation       Adetayo et al. 2012 (US)         Breast operations (N=10,471)       4.0       Previous re-operation       de Biacam et al. 2012 (US)         Lumpectomy (n=16,517)       1.6       Risks: BMI >25; ASA <u>&gt;3;</u> DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking       Davis et al. 2013 (US)         Breast-conserving operations (N=72,058)       3.6       90 day SSI rate       Oisen et al. 2015 (US)         Breast operation (n=72,050)       2.4       90 day SSI-rate       Saeed et al. 2015 (US)         Mastectomy +	(n=27)	3.7	NNIS risk >1, no PDS	
Breast operations (N=949) Mastectomy + Implant Mastectomy + reconstruction Mastectomy only       12.4 (A.4) Breast reduction       Risks: DM, BMI > 30, Implant, central venous catheter       Olsen et al. 2008 (US)         Breast cancer operations (N=2,338)       18.9       Risks: chemo radiation, hematoma, BMI > 30 Duration cut point > 3h       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N=199)       19.1       Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Angarita et al. 2011 (Columbia)         Breast reconstructions (N=297)       7.7       Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Adetayo et al. 2012 (US)         Breast reconstructions (N=297)       7.7       Risks: high BMI, Smoking, DM, previous re-operation       Adetayo et al. 2012 (US)         Breast operations (N=26,988) (N=38,739)       5.6       High BMI, Smoking, DM, previous re-operation       Adetayo et al. 2012 (US)         Breast-conserving operations (N=38,739)       2.3       Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking       Davis et al. 2013 (US)         Breast-conserving operations (N=72,058)       3.6       90 day SSI rate       Olsen et al. 2015 (US)         Breast operations (N=72,058)       3.6       90 day SSI-rate       Saeed et al. 2015 (US)         Mastectomy + fiap (n=4,055)       4.8       90 day SSI-rate       Saeed et al. 2015 (US) <td>Mastectomy / mammary tumorectomy (n=2,438)</td> <td>2.7</td> <td></td> <td>Rioux et al. 2007 (France)</td>	Mastectomy / mammary tumorectomy (n=2,438)	2.7		Rioux et al. 2007 (France)
Mastectomy + Implant Mastectomy + reconstruction Mastectomy only Breast reduction       12.4 6.2 4.4 1.1       Risks: DM, BMI > 30, Implant, central venous catheter       Oisen et al. 2008 (US)         Breast cancer operations (N=2,338)       18.9       Risks: chemo radiation, hematoma, BMI > 30 Duration cut point > 3h       Viiar-Compte et al. 2009 (Mexico)         Breast cancer operations (N=199)       19.1       Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Angarita et al. 2011 (Columbia)         Breast reconstructions (N=297)       7.7       Risks: high BMI, Smoking, DM, previous re-operation       Adetayo et al. 2012 (US)         Breast operations (N=26,988) Mastectomy (n=10,471) Lumpectomy (n=16,517)       5.6 High BMI, Smoking, DM, previous re-operation       Adetayo et al. 2012 (US)         Breast-conserving operations (N=38,739)       2.3       Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>n</sup> percentile (> 2 h), smoking       Davis et al. 2013 (US)         Breast-conserving operations Primary operation (n=23,001) Re-operation (n=5,826) Adstectomy (n=3,447)       1.8 90 day SSI rate       Oisen et al. 2015 (US)         Breast operations (N=72,058) Mastectomy + fiap Mastectomy + fiap (n=4,065)       4.8 4.8 Mastectomy + fiap       90 day SSI-rate       Saeed et al. 2015 (US)	Breast operations (N=949)			
Mastectomy + reconstruction Mastectomy only Breast reduction       6.2 4.4 1.1       implant, central venous catheter         Breast reduction       4.4 1.1       implant, central venous catheter       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N-2,338)       18.9       Risks: chemo radiation, hematoma, BMI > 30 Duration cut point > 3h       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N-199)       19.1       Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Angarita et al. 2011 (Columbia)         Breast reconstructions (N-297)       7.7       Risks: high BMI, DM smoking, Skin disorder, tumour at high stage, neoadjuvant therapy       Adetayo et al. 2012 (US)         Breast operations (N-26,988)       5.6       High BMI, Smoking, DM, previous re-operation       Adetayo et al. 2012 (US)         Mastectomy (n=16,517)       1.6       Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking       Davis et al. 2013 (US)         Breast-conserving operations Primary operation       (n=5,826)       2.4       Oisen et al. 2015 (US)         Breast operations (N=72,058)       3.6       90 day SSI rate       Saeed et al. 2015 (US)         Mastectomy + flap       (n=4,065)       4.8       90 day SSI-rate       Saeed et al. 2015 (US)	Mastectomy + Implant	12.4	Risks: DM, BMI > 30,	Olsen et al. 2008 (US)
Breast reduction       1.1       Calified         Breast reduction       1.1       Risks: chemo radiation, hematoma, BMI >30 Duration cut point > 3h       Vilar-Compte et al. 2009 (Mexico)         Breast cancer operations (N=2,338)       18.9       Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Angarita et al. 2011 (Columbia)         Breast reconstructions (N=297)       7.7       Risks: high BMI, DM, smoking, Skin disorder, tumour at high stage, neoadjuvant therapy       Adetayo et al. 2012 (US)         Breast operations (N=26,988)       5.6       High BMI, Smoking, DM, previous re-operation       Adetayo et al. 2012 (US)         Breast compt (n=10,471)       4.0       previous re-operation       de Blacam et al. 2012 (US)         Lumpectomy (n=16,517)       1.6       Risks: BMI >25; ASA >3; DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking       Davis et al. 2013 (US)         Breast-conserving operations       1.8       90 day SSI rate       Olsen et al. 2015 (US)         Breast operations (N=2,058)       3.6       90 day SSI rate       Saeed et al. 2015 (US)         Breast operations (N=2,058)       3.6       90 day SSI rate       Saeed et al. 2015 (US)	Mastectomy + reconstruction	6.2	Implant, central venous	
Breast cancer operations (N=2,338)     18.9     Risks: chemo radiation, hematoma, BMI >30 Duration cut point > 3h     Vilar-Compte et al. 2009 (Mexico)       Breast cancer operations (N=199)     19.1     Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy     Angarita et al. 2011 (Columbia)       Breast reconstructions (N=297)     7.7     Risks: high BMI, DM     Adetayo et al. 2012 (US)       Breast operations (N=26,988)     5.6     High BMI, Smoking, DM, previous re-operation     Adetayo et al. 2012 (US)       Breast operations (N=16,517)     1.6     High BMI, Smoking, DM, previous re-operation     de Biacam et al. 2012 (US)       Mastectomy no reconstruction (N=38,739)     2.3     DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking     Davis et al. 2013 (US)       Breast operation (N=3,825)     1.8     90 day SSI rate     Oisen et al. 2015 (US)       Breast operations (N=72,058)     3.6     90 day SSI-rate     Saeed et al. 2015 (US)       Mastectomy + flap (n=4,065)     4.8     90 day SSI-rate     Saeed et al. 2015 (US)	Breast reduction	1.1	cauleter	
Breast cancer operations (N=2,338)18.9Risks: chemo radiation, hematoma, BMI >30 Duration cut point > 3hVilar-Compte et al. 2009 (Mexico)Breast cancer operations (N=199)19.1Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapyAngarita et al. 2011 (Columbia)Breast reconstructions (N=297)7.7Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapyAdetayo et al. 2012 (US)Breast operations (N=26,988) Mastectomy (n=16,517)5.6High BMI, Smoking, DM, previous re-operationAdetayo et al. 2012 (US)Mastectomy no reconstruction (N=38,739)2.3Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>h</sup> percentile (> 2 h), smokingDavis et al. 2013 (US)Breast-conserving operations Primary operation Re-operation1.890 day SSI rateOisen et al. 2015 (US)Breast operations Mastectomy + flap Mastectomy + flap (n=4,065)3.6 4.890 day SSI-rateSaeed et al. 2015 (US)				
Breast cancer operations (N=2,336)       10.9       Inernational, BMI > 30       Vital=Comptend and Comptend and Com	Emperies an empirican (NL-2, 229)	10.0	Risks: chemo radiation,	Milar Compto et al. 2000
Breast cancer operations (N=199)     19.1     Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy     Angarita et al. 2011 (Columbia)       Breast reconstructions (N=297)     7.7     Risks: high BMI; DM     Adetayo et al. 2012 (US)       Breast operations (N=26,988)     5.6     High BMI, Smoking, DM, previous re-operation     Adetayo et al. 2012 (US)       Breast operations (n=10,471)     4.0     previous re-operation     de Blacam et al. 2012 (US)       Lumpectomy (n=16,517)     1.6     Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>h</sup> percentile (> 2 h), smoking     Davis et al. 2013 (US)       Breast-conserving operations Primary operation     (n=3,2001)     1.8     90 day SSI rate     Olsen et al. 2015 (US)       Breast operations (N=72,058)     3.6     90 day SSI rate     Saeed et al. 2015 (US)       Mastectomy + flap     (n=4,065)     4.8     90 day SSI-rate     Saeed et al. 2015 (US)	Breast cancer operations (N=2,338)	16.9	Duration cut point > 3b	(Mexico)
Breast cancer operations (N=199)     19.1     Risks: high BMI, DM, smoking, skin disorder, tumour at high stage, neoadjuvant therapy     Angarita et al. 2011 (Columbia)       Breast reconstructions (N=297)     7.7     Risks: high BMI; DM     Adetayo et al. 2012 (US)       Breast operations (N=26,988)     5.6     High BMI, Smoking, DM, previous re-operation     Adetayo et al. 2012 (US)       Breast operations (n=10,471)     4.0     previous re-operation     de Blacam et al. 2012 (US)       Lumpectomy (n=16,517)     1.6     Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>h</sup> percentile (> 2 h), smoking     Davis et al. 2013 (US)       Breast-conserving operations Primary operation     1.8     90 day SSI rate     Oisen et al. 2015 (US)       Breast operations (N=72,058)     3.6     90 day SSI-rate     Saeed et al. 2015 (US)       Mastectomy + flap     (n=4,065)     4.8     90 day SSI-rate     Saeed et al. 2015 (US)			Buraton out point - on	(1100)
Breast cancer operations (N=199)       19.1       Smoking, skin disorder, tumour at high stage, neoadjuvant therapy       Argania et al. 2011 (Columbia)         Breast reconstructions (N=297)       7.7       Risks: high BMI; DM       Adetayo et al. 2012 (US)         Breast operations (N=26,988)       5.6       High BMI, Smoking, DM, previous re-operation       de Blacam et al. 2012 (US)         Mastectomy (n=10,471)       4.0       previous re-operation       de Blacam et al. 2012 (US)         Mastectomy no reconstruction       (N=38,739)       2.3       DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking       Davis et al. 2013 (US)         Breast-conserving operations       (N=38,739)       1.8       90 day SSI rate       Oisen et al. 2015 (US)         Breast operation       (n=5,826)       2.4       90 day SSI rate       Oisen et al. 2015 (US)         Breast operations       (n=7,447)       2.3       90 day SSI rate       Saeed et al. 2015 (US)         Mastectomy + flap       (n=4,065)       4.8       5.1       5.1       5.1	Employee and the second second second	10.1	Risks: high BMI, DM,	Assertia et al. 0044
Breast reconstructions (N=297)     7.7     Risks: high BMI; DM     Adetayo et al. 2012 (US)       Breast operations (N=26,988)     5.6     High BMI, Smoking, DM, Mastectomy (n=10,471)     4.0     previous re-operation     de Blacam et al. 2012 (US)       Lumpectomy (n=16,517)     1.6     Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>h</sup> percentile (> 2 h), smoking     Davis et al. 2013 (US)       Breast-conserving operations     (N=38,739)     2.3     DM; operation time> 75 <sup>h</sup> percentile (> 2 h), smoking     Davis et al. 2013 (US)       Breast-conserving operations     1.8     90 day SSI rate     Oisen et al. 2015 (US)       Breast operations (N=72,058)     3.6     90 day SSI rate     Saeed et al. 2015 (US)       Mastectomy + flap     (n=4,065)     4.8     4.8     Saeed et al. 2015 (US)	Breast cancer operations (N=199)	19.1	turnous at blob stage	(Columbia)
Breast reconstructions (N=297)         7.7         Risks: high BMI; DM         Adetayo et al. 2012 (US)           Breast operations (N=26,988)         5.6         High BMI, Smoking, DM, previous re-operation         de Blacam et al. 2012 (US)           Lumpectomy (n=10,471)         4.0         previous re-operation         de Blacam et al. 2012 (US)           Mastectomy no reconstruction         N=38,739)         2.3         Risks: BMI >25; ASA ≥3; DM; operation time> 75 <sup>h</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations         Primary operation         (n=23,001)         1.8         90 day SSI rate         Oisen et al. 2015 (US)           Breast operations         (n=3,447)         2.3         90 day SSI rate         Saeed et al. 2015 (US)           Mastectomy + flap         (n=4,065)         4.8         4.8         Saeed et al. 2015 (US)			neoadiuvant therapy	(Columbia)
Breast operations (N=26,988) Mastectomy (n=10,471) Lumpectomy (n=16,517)         5.6 4.0 1.6         High BMI, Smoking, DM, previous re-operation         de Blacam et al. 2012 (US)           Mastectomy no reconstruction (N=38,739)         1.6         Risks: BMI >25; ASA >3; DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations Primary operation Re-operation         1.8 90 day SSI rate         Oisen et al. 2015 (US)           Breast operations Mastectomy         (n=3,447) (n=4,065)         3.6 4.8 Mastectomy + flap         90 day SSI-rate	Breast reconstructions (N=297)	7.7	Risks: high BMI; DM	Adetavo et al. 2012 (US)
Mastectomy (n=10,471) Lumpectomy (n=16,517)         4.0 1.6         prévious re-operation         de Blacam et al. 2012 (US)           Mastectomy no reconstruction (N=38,739)         1.6         Risks: BMI >25; ASA >3; DM; operation time> 75 <sup>h</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations Primary operation (n=5,826)         1.8         90 day SSI rate         Olsen et al. 2015 (US)           Breast operations Mastectomy         (n=3,447)         2.3         90 day SSI rate         Saeed et al. 2015 (US)           Mastectomy + flap Mastectomy + flap (n=4,065)         4.8         90 day SSI-rate         Saeed et al. 2015 (US)	Breast operations (N=26,988)	5.6	High BMI, Smoking, DM,	
Lumpectomy (n=16,517)         1.6           Mastectomy no reconstruction (N=38,739)         Risks: BMI >25; ASA <u>&gt;3;</u> DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations Primary operation Re-operation         1.8         90 day SSI rate         Oisen et al. 2015 (US)           Breast operations Mastectomy         (n=2,001)         1.8         90 day SSI rate         Oisen et al. 2015 (US)           Breast operations Mastectomy + flap         (n=4,065)         4.8         90 day SSI-rate         Saeed et al. 2015 (US)	Mastectomy (n=10,471)	4.0	previous re-operation	de Blacam et al. 2012 (US)
Mastectomy no reconstruction (N=38,739)         Risks: BMI >25; ASA >3; DM; operation time> 75 <sup>th</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations Primary operation Re-operation         1.8 (n=23,001)         90 day SSI rate         Olsen et al. 2015 (US)           Breast operations Mastectomy         (n=72,058)         3.6 (n=4,065)         90 day SSI-rate         Saeed et al. 2015 (US)	Lumpectomy (n=16,517)	1.6		
(N=38,739)         2.3         DM; operation time> 75 <sup>n</sup> percentile (> 2 h), smoking         Davis et al. 2013 (US)           Breast-conserving operations Primary operation (n=23,001) Re-operation (n=5,826)         1.8         90 day SSI rate         Oisen et al. 2015 (US)           Breast operations Mastectomy         (n=3,447)         2.3         90 day SSI rate         Oisen et al. 2015 (US)           Mastectomy + flap Mastectomy + flap Mastectomy + implant (n=4,065)         4.8         90 day SSI-rate         Saeed et al. 2015 (US)	Mastectomy no reconstruction		Risks: BMI >25; ASA >3;	
Breast-conserving operations         Primary operation         1.8         90 day SSI rate         Oisen et al. 2015 (US)           Breast operation         (n=5,826)         2.4         90 day SSI rate         Oisen et al. 2015 (US)           Breast operations         (N=72,058)         3.6         90 day SSI rate         Oisen et al. 2015 (US)           Mastectomy         (n=4,065)         4.8         4.8         Saeed et al. 2015 (US)           Mastectomy + Implant (n=18,300)         5.1         5.1         5.1	(N=38,739)	2.3	DM; operation time> 75 <sup>n</sup>	Davis et al. 2013 (US)
Breast-conserving operations         1.8         90 day SSI rate         Oisen et al. 2015 (US)           Re-operation         (n=5,826)         2.4         Oisen et al. 2015 (US)           Breast operations         (N=72,058)         3.6         Oisen et al. 2015 (US)           Mastectomy         (n=3,447)         2.3         90 day SSI-rate         Saeed et al. 2015 (US)           Mastectomy + flap         (n=4,065)         4.8         Saeed et al. 2015 (US)         Saeed et al. 2015 (US)			percentile (> 2 h), smoking	
Primary operation         (n=23,001)         1.8         90 day SSI rate         Olsen et al. 2015 (US)           Re-operation         (n=5,826)         2.4         90 day SSI rate         Olsen et al. 2015 (US)           Breast operations         (N=72,058)         3.6         90 day SSI rate         Saeed et al. 2015 (US)           Mastectomy         (n=3,447)         2.3         90 day SSI-rate         Saeed et al. 2015 (US)           Mastectomy + flap         (n=4,065)         4.8         Saeed et al. 2015 (US)	Breast-conserving operations	1		
Re-operation         (n=5,826)         2.4           Breast operations         (N=72,058)         3.6           Mastectomy         (n=3,447)         2.3         90 day SSI-rate         Saeed et al. 2015 (US)           Mastectomy + flap         (n=4,065)         4.8         Mastectomy + Implant         (n=18,300)         5.1	Primary operation (n=23,001)	1.8	90 day SSI rate	Olsen et al. 2015 (US)
Breast operations         (N=72,058)         3.6           Mastectomy         (n=3,447)         2.3         90 day SSI-rate         Saeed et al. 2015 (US)           Mastectomy + flap         (n=4,055)         4.8         Mastectomy + implant         (n=18,300)         5.1	Re-operation (n=5,826)	2.4		
Mastectomy         (n=3,447)         2.3         90 day SSI-rate         Saeed et al. 2015 (US)           Mastectomy + flap         (n=4,055)         4.8         Mastectomy + implant         (n=18,300)         5.1	Breast operations (N=72,058)	3.6		
Mastectomy + nap (1=4,05) 4.6 Mastectomy + Implant (n=18,300) 5.1	Mastectomy (n=3,447)	2.3	90 day SSI-rate	saeed et al. 2015 (US)
	Mastectomy + nap (n=4,065) Mastectomy + implant (n=18.300)	5.1		

(6 with permission of the copy right holder)

111

BMI- body mass index; DM - Diabetes Mellitus; PDS - Post Discharge Surveillance

Re-operation as a SSI-risk in breast surgery

- The risk for SSI after re-operations is reported significantly higher than after primary operations (13,14,17).
- In our retrospective register-based survey, re-operated patients had 2.6-fold (P = 0.003), 2.4-fold (P = 0.017) and 2.7-fold (P = 0.027) risk for SSI compared with primary operated patients among all operated patients, local excision, and mastectomy patients respectively (13).
- In a US cohort study (17), the SSI incidence was 2-fold higher after mastectomy with immediate reconstruction than after mastectomy alone. Only 49% of SSIs were detected within 30-days postoperatively.
- In a study of Throckmorton et al. in 2009 (19) there was no statistically significant association between prior operation within 90 days and SSI rate (P = 1.0).

Procedure specific complications in breast surgery

- Axillary lymph node dissection (ALND) is a classical procedure often completed as a reoperation requiring an additional incision with under arm location (20,21).
- In a Cochrane Review, ALND is reported resulting more likely lymphoedema compared with Sentinel Lymph Node Biopsy (SLNP) with no significant differences in overall survival of the operated patients. Full axillary clearance without clinically and radiologically involved axilla is no longer considered acceptable practice (20).
- A recent study challenged the high costs and long operative time of standard procedures by suggesting possibility to avoid intraoperative Frozen Section (iFS) in most cases of early-stage clinically and radiographically node-negative breast cancer patients without a significant impact on the overall quality of treatment and standard of care (21).

#### Procedure specific complications in breast surgery

- Breast reconstruction has a positive impact on the body image and quality of life for women after experiencing the physically and psychologically demanding processes (22) but the positive experience may be threatened by postoperative complications.
- Impaired wound healing (18.3%), seroma (6.1%), haematoma (4.6%), capsular contraction (4.6%) and infection (3.8%) reported existing after breast reconstruction operations (23).
- Postoperative complications, 3.1-fold (P = 0.017) SSI rates or impaired healing; 3.8-fold (P = 0.020) SSI or impaired healing requiring surgery reported due to the implant used as a temporary spacer for delayed immediate autologous reconstruction compared with no spacer. The explantation of the implant occurred after 16.3% of procedures. Other risks for complications were the surgeon, higher drain volume during the last 24 h, higher implant volumes, higher resection weight, and incision type. (24)
- In a study of Alves et al. published in 2022, no significant differences reported in haematomas, infections, flap necrosis, and in partial or total flap loss between immediate and delayed deep inferior epigastric perforator flap operations but higher prevalence of wound healing issues (healing delayed, dehiscence, and superficial skin necrosis) in delayed breast reconstructions, probably linked to complex care processes including radiation or chemotherapy interfering the healing process. (25)

#### Surgical drains as SSI risks in breast surgery

- After breast operations, patients usually have one or more surgical drains removing bleeding and leak from the surgical site. The criteria for drain removal vary. Some surgeons remove the drain according to the postoperative day (E.G. day 3), some by drain volume (E.G. 30 ml) per day or per patient defined criteria.
- Drain volume is reported varying according to the surgical interventions and techniques used. After the subcutaneous placement of breast implants or expanders after a mastectomy without biological matrices or synthetic meshes the drains remained for a mean of 5.9 days (SD 3.1), producing a mean cumulative volume of 458.3 ml (SD 521.9) with the mean volume of 16.7 ml (SD 11.5) within the last 24 hours. The association between the high drain volume during the last 24 h and explantation of the breast implant was reported statistically significant (P = 0.045). (23)
- In our study, the existence of a surgical drain predicted 3.3-fold (P = 0.003) risk for SSI among all breast operated patients and 3.2- fold (P = 0.008) risk was among local excision patients. Among mastectomy-patients the risk was not statistically significant. (13)

Variations in measuring patient related SSI-risks in breast surgery

- In a recent US study, the variation in SSI rates reported in association with chronic obstructive pulmonary disease (COPD), diabetes, smoking, ASA class-severe, BMI > 35 kg / m<sup>2</sup>, and length of hospital stay (LOS) more than one day (9).
- > BMI > 25 kg /  $m^2$  was reported as a risk for SSI in lobectomies and mastectomies (13).
- BMI > 30 kg / m<sup>2</sup> was not reported as a risk following implant-based breast reconstructions (19).
- In a large scale studies, the BMI > 35 kg / m<sup>2</sup> in addition to smoking and DM, were reported as SSI-risks in lumpectomies and mastectomies (9,14).

## Examples of SSI-risks in breast surgery with debatable evidence

- The breast cancer patients' preoperative hospital visits include invasive interventions like core needle biopsy, and placement of a wire or other localizing device prior to the surgical procedure challenging the requirement for intact skin in the operational site but not having clear association with SSI (9).
- In our past study in lobectomy and mastectomy patients (N=982) nurses reported the skin of the patient in the surgical site intact for 80% of the operations, and signs of preoperative infection in six per cent. Nurses documented preoperative invasive procedures in 55% of the operations. A sentinel puncture was completed in 10% of the operations, wire marking in 35% and other punctures (e.g. blue ink application) in three per cent of the operations. The rest of the patients had anaesthesia-related punctures.(13)
- The evidence related to the risk of preoperative invasive procedures is not free from bias due to the challenges in retrospective data collection and documentation (13,9).

#### Conclusions

- Securing aseptic safety in breast operations is important due to the variation in the numerous general, patient and the procedure related SSI-risks.
- It is crucial to further develop procedure specific process indicators enabling the implementation and measurement of patient, occupational and environmental aseptic safety in breast surgery.
- The implementation and follow-up of procedure specific infection prevention and control measures require relevant structure indicators and evaluation models validated in breast surgery.

#### References

- Metsälä E, Schroderus-Salo T, Straume K, Strom B, Marmy L, Øynes M, Pires Jorge JA, Randle L, Kivistik S. The Factors for Success and Lack of Success in the Breast Cancer Patient Care Pathway: A Qualitative Study From the Health Care Staff Perspective. Eur J Breast Health. 2022 Jul 1;18(3):222-228. doi: 10.4274/ejbh.galenos.2022.2022-3-1. PMID: 35855191; PMCID: PMC9255659
- 2. Metsälä E, Kivistik S, Straume K, Marmy L, Jorge JAP, Strom B. Breast cancer patients' experiences on their individual care pathway: A qualitative study. Radiography (Lond). 2022 Aug;28(3):697-703. doi: 10.1016/j.radi.2022.06.002. Epub 2022 Jun 20. PMID: 35738048.
- 3. Héquet, D., Huchon, C., Baffert, S. *et al.* Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators. *Br J Cancer* **116**, 1394–1401 (2017). <u>https://doi.org/10.1038/bjc.2017.114</u>
- 4. Biganzoli L, Cardoso F, Beishon M, Cameron D, Cataliotti L, Coles CE, Delgado Bolton RC, Trill MD, Erdem S, Fjell M, Geiss R, Goossens M, Kuhl C, Marotti L, Naredi P, Oberst S, Palussière J, Ponti A, Rosselli Del Turco M, Rubio IT, Sapino A, Senkus-Konefka E, Skelin M, Sousa B, Saarto T, Costa A, Poortmans P. The requirements of a specialist breast centre. Breast. 2020 Jun;51:65-84. doi: 10.1016/j.breast.2020.02.003. Epub 2020 Feb 26. PMID: 32217457; PMCID: PMC7375681.
- 5. Aholaakko, T. K., Metsälä, E., Sihvonen, M. & Lyytikäinen, O. 2013. Risk factors for surgical site infection in breast surgery. Journal of Clinical Nursing 22: 948-57. https://onlinelibrary.wiley.com/doi/10.1111/jocn.12009
- 6. Aholaakko, Teija-Kaisa. 2018. Intraoperative aseptic practices and surgical site infections in breast surgery. Academic Dissertation. University of Helsinki. Medical Faculty. Doctoral School Health. Population Health Programme. Available at: <a href="https://helda.helsinki.fi/handle/10138/249327">https://helda.helsinki.fi/handle/10138/249327</a>
- 7. Aholaakko, T. K. & Metsälä, E. 2016. Reasoning for adherence to aseptic practices in the operating room. Global Anesthesia and Perioperative Medicine 2(4): 216-222.
- 8. Yap & De La Serna. 2020. Outcomes of Sentinel Lymph Node Biopsy Using Blue Dye Method for Early Breast Cancer A Single-Institution Experience in the Philippines. Breast Cancer: Targets and Therapy. <u>https://www.dovepress.com/outcomes-of-sentinel-lymph-node-biopsy-using-blue-dye-method-for-early-peer-reviewed-fulltext-article-BCTT</u>
- 9. Pastoriza J, McNelis J, Parsikia A, et al. Predictive factors for surgical site infections in patients undergoing surgery for breast carcinoma. *Am Surg.* 2021;87(1):68-76. https://www.proquest.com/scholarly-journals/predictive-factors-surgical-site-infections/docview/2515010543/se-2. doi: <a href="https://doi.org/10.1177/0003134820949996">https://doi.org/10.1177/0003134820949996</a>.
- 10. European Council COUNCIL RECOMMENDATION of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections <a href="https://eur-lex.europa.eu/LexUriServ/L
- 11. European Centre for Disease Prevention and Control (ECDC). 2022. Healthcare-associated infections in acute care hospitals. <u>Healthcare-associated infections in acute care hospitals (europa.eu)</u>
- 12.National Nosocomial Infections Surveillance (NNIS). 1986. National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998. A report from NNIS System. Hospital Infection Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia.

#### References

- 13. Centers for Disease Control and Prevention (CDC). National Nosocomial Infection Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. AM J Infect Control 2004; 32: 470-485.
- 14. de Blacam, C., Ogunleye, A.A., Momoh, A.O. et al. 2012. High body mass index and smoking predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the National surgical quality improvement program database. Ann Surg. 255(3):551-555. doi: 10. 1097/ SLA. 0b013e31 8246c294
- 15. Gaynes, R.P., Culver, D.H., Horan, T.C., Edwards, J.R., Richards, C., Tolson, J.S. and the National Nosocomial Infections Surveillance System. 2001. Surgical Site Infection (SSI) Rates in the United States, 1992–1998: The National Nosocomial Infections Surveillance System Basic SSI Risk Index. Clinical Infectious Diseases 2001; 33(Suppl 2):S69–77.
- 16. Prospero, E., Cavicci, A., Bacelli, S. et al. 2006. Surveillance for Surgical Site Infection After Hospital Discharge: A Surgical Procedure-Specific Perspective. Infect Control Hosp Epidemiol 27: 1313-1317.
- 17. Olsen, M.A., Nickel, K.B., Fox, I.K., Margenthaler, J.A., Ball, K.E., Mines, D., Wallace, A.E. & Fraser, V.J. 2015. Incidence of surgical site infection following mastectomy with and without immediate reconstruction using private insurer claims data. Infect Control Hosp Epidemiol, 36 (8), 907–914.
- 18. Vilar-Compte, D., Rosales, S., Hernandez-Mello, N., Maafs, E. & Volkow, P. 2009. Surveillance, control, and prevention of surgical site infections in breast cancer surgery: A 5-year experience. Am J Infect Control, 37, 674-679.
- 19. Throckmorton, A.D., Boughey, J.C., Boostrom, S.Y., Holifield, A.C., Stobbs, M.M., Hoskin, T., Baddour, L.M. & Degnim, A.C. 2009. Postoperative Prophylactic Antibiotics and Surgical Site Infection. Rates in Breast Surgery Patients. Ann Surg Oncol (2009) 16:2464–2469 DOI 10.1245/s10434-009-0542-1
- 20. Bromham, N., Schmidt-Hansen, M., Astin, M., Hasler, E. & Reed, M.W. Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev. 2017 Jan 4;1(1):CD004561. doi: 10.1002/14651858.CD004561.pub3. PMID: 28052186; PMCID: PMC6464919.
- 21. Lerttiendamrong, B., Treeratanapun, N., Vacharathit, V., Tantiphlachiva, K., Vongwattanakit, P., Manasnayakorn, S. & Vongsaisuwon, M. Is Routine Intraoperative Frozen Section Analysis of Sentinel Lymph Nodes Necessary in Every Early-Stage Breast Cancer?. *Breast Cancer (Dove Med Press)*. 2022;14:281-290 <a href="https://doi.org/10.2147/BCTT.S380579">https://doi.org/10.2147/BCTT.S380579</a>
- 22. Mégevand, V., Scampa, M., McEvoy, H., Kalbermatten, D.F. & Oranges, C.M. 2022. Comparison of Outcomes Following Prepectoral and Subpectoral Implants for Breast Reconstruction: Systematic Review and Meta-Analysis. Cancers 14, 4223. <u>https://doi.org/10.3390/</u> cancers14174223
- 23. Leitner, H.S.; Pauzenberger, R.; Ederer, I.A.; Radtke, C.; Hacker, S. 2021. BMI Specific Complications Following Implant-Based Breast Reconstruction after Mastectomy. J. Clin. Med. 2021, 10, 5665. https://doi.org/10.3390/jcm10235665
- 24. Pfob, A., Koelbel, V., Schuetz, F., Feißt, M., Blumenstein, M., Hennigs, A. Golatta, M. & Heil, J. 2020. Surgeon's preference of subcutaneous tissue resection: most important factor for short-term complications in subcutaneous implant placement after mastectomy—results of a cohort study. Archieves of Gynecology and Obstetrics. 301: 1037-1045. https://doi.org/10.1007/s00404-020-05481-x
- 25. Alves, A.S., Tan, V., Scampa, M., Kalbermatten, D.F. & Oranges, C.M. 2022. Complications of Immediate versus Delayed DIEP Reconstruction: A Meta-Analysis of Comparative Studies. Cancers 14, 4272. <a href="https://doi.org/10.3390/cancers14174272">https://doi.org/10.3390/cancers14174272</a>

# Author

Teija-Kaisa Aholaakko, PhD, LicEd, RN (specialised)



# Thank you all for this opportunity to share my interests with all the e-Breast 11 partners!





Austausch und Mobilität Echanges et mobilité Scambi e mobilità Exchange and mobility







Hes.so Haute Ecole Spécialisée de Suisse occidentale Fachhochschule Westschweiz University of Applied Sciences and Arts

Western Switzerland





Western Norway University of Applied Sciences

